Drug Discovery

#CAR-T #Cell and gene therapy #Collaboration #Drug development #Drug discovery

Sitting down with… Julian Cole, Cell & Gene Collective 

The Cell & Gene Collective publicly launched in May 2021. Lu Rahman caught up with Julian Cole, Country Medical Director of Gilead Sciences for the UK and Ireland to find out more about this cross-industry alliance between Astellas, bluebird bio, Bristol Myers Squibb, Kite (a Gilead company) and Novartis. Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Drug discovery #Neuroscience #Psychedelics

Experienced neuroscientist joins Beckley Psytech as CMO 

Beckley Psytech, a clinical stage, biotechnology company dedicated to addressing neuropsychiatric disorders through the novel application of psychedelic medicines, has appointed Frank Wiegand as Chief Medical Officer.  Dr. Wiegand, a trained neurologist and neuroscientist, joins Beckley Psytech after more than 20 years with Janssen (a Johnson & Johnson company), where… Read More

#News

Handshake
#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

BioNet and BIA Separations collaborate to develop mRNA vaccines 

BioNet and BIA Separations, now part of Sartorius, have developed an optimised mRNA manufacturing process.   BIA’s expertise in chromatographic columns for mRNA purification combined with BioNet’s expertise in the product development of genetic vaccines have, since early 2021, enabled both teams to collaborate on the optimisation and upscale of a high-yield… Read More

#News

#Drug discovery #High content imaging #Imaging #Podcast

Podcast: Analysing the technology driving innovation in drug discovery

The latest free-to-listen DDW podcast episode is titled “Analysing the technology driving innovation in drug discovery”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas.  These articles are titled: “How imaging techniques… Read More

#Editor's Choice #News

#Drug development #Funding #Health #Healthcare #Public health

UK budget plans: healthcare industry reaction 

In the Autumn 2021 budget delivered by UK Chancellor of the Exchequer, Rishi Sunak, on 27 October, the Government announced a range of measures designed to benefit UK science, business, and technology. This, at a time where the UK’s health service will need to tackle backlogs through the Winter… Read More

#News #Trending News

#Biopharmaceuticals #Drug delivery #Drug development

Abcam acquires BioVision and expands kit 

Abcam has completed a $340m strategic acquisition of BioVision and doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, Oregon. This enhanced capacity is another component of Abcam’s growth in the US, which the company says will enable it to support the research and biopharma… Read More

#News

#Alzheimer's #Drug discovery #Genetics #Life sciences #Neuroscience #Therapeutics

Is new thinking the key to unlocking Alzheimer’s treatment?

Professor Paul Whiting, Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI), and Stephane Martinez, product manager and neuroscience expert in PerkinElmer’s Life Sciences segment, share expert insights on Alzheimer’s Disease research today and where discovery and therapeutic approaches might be headed next. Read More

#Editor's Choice #News #Opinion

#Drug development #Drug discovery #Funding #Therapeutics

Researchers awarded $12 million for personalised asthma therapies

A group of researchers led by Indiana University School of Medicine’s Benjamin Gaston has been awarded a research programme project grant from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalised… Read More

#News

#AI #Drug development #Drug discovery #Machine learning #Therapeutics

Why we are on the cusp of a golden age of medicine 

Listen to this article on the DDW Podcast:   Panna Sharma is the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics. Lu Rahman spoke to the man behind this biotech to find… Read More

#Cancer Research #Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Biology #Drug development #Infectious diseases #MPS technology #Novel therapeutics #Organ-on-a-chip #Toxicology

Hype or hope – microphysiological systems?

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Collaboration #Drug discovery

This week in drug discovery (25-29 October)  

News round-up by DDW’s Megan Thomas for 25-29 October   DDW’s Megan Thomas has selected five stories which highlight the results that can be achieved through collaboration in the drug discovery sector.    1. Australian researchers identify new pathways to target breast cancer  A… Read More

#News #Trending News

#Biologics / Biotechnology #Cancer immunotherapy #Drug discovery #Flow Cytometry #Immuno-oncology #Webinar

Webinar offers insight into pharmacological reactions

Dr Nina Senutovitch, Senior Scientist, Sartorius, notes that more efficient and powerful tools are critical for furthering the development of highly target-specific immunotherapies, such as adoptive cell transfer therapies. These include Chimeric Antigen Receptor T cells (CAR-T), that harness an individual’s own immune system to attack cancerous cells. … Read More

#News #Trending News

#Biomedicine #Biopharmaceutical #Drug discovery #Mass spectrometry / NMR

Partnership to accelerate clone selection and process development 

Waters Corporation and Sartorius have partnered to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.   The partnership will implement the BioAccord LC-MS System from Waters as a new bioprocess analyser with data connectivity to Sartorius’… Read More

#News

Seed funding
#Alzheimer's #Clinical trials #Drug discovery #Funding

€9 million to address ‘Agitation/Aggression’ in Alzheimer’s

Exciva has closed a Series A financing of €9 million, led by Andera Partners, to develop the lead compound up to completion of Phase I. The product has the potential to treat behavioral and psychological symptoms in Alzheimer disease patients. This compound is the combination of two clinically validated products,… Read More

#News